BACKGROUND: Richter syndrome (RS) is the development of an aggressive lymphoid malignancy, in chronic lymphocytic leukemia (CLL). Most are diffuse large B-cell lymphomas (DLBCL), however in 10-15% of RS, there is transformation to Hodgkin lymphoma, termed "Hodgkin variant" (HV). In the present retrospective study we summarize the Israeli experience with HV-RS, and analyze demographic data, relevant laboratory and clinical parameters, and outcome. PATIENTS AND METHODS: We collected and analyzed data from 119 patients with RS from 12 Centers in Israel during 1996-2010 and identified 16 cases with "Hodgkin's variant". RESULTS: The median age was 58 years, and 67% were males. The median time from CLL diagnosis to development of HV was 5.9 (range=0.8-11.9) years and the median survival was 39.5 months, compared to 9 months for the cases with RS-DLBCL. CONCLUSION: Hodgkin variant appears to differ from DLBCL-RS and is clinically less aggressive. However, compared to de novo Hodgkin's lymphoma, HV-RS has a worse prognosis.
BACKGROUND:Richter syndrome (RS) is the development of an aggressive lymphoid malignancy, in chronic lymphocytic leukemia (CLL). Most are diffuse large B-cell lymphomas (DLBCL), however in 10-15% of RS, there is transformation to Hodgkin lymphoma, termed "Hodgkin variant" (HV). In the present retrospective study we summarize the Israeli experience with HV-RS, and analyze demographic data, relevant laboratory and clinical parameters, and outcome. PATIENTS AND METHODS: We collected and analyzed data from 119 patients with RS from 12 Centers in Israel during 1996-2010 and identified 16 cases with "Hodgkin's variant". RESULTS: The median age was 58 years, and 67% were males. The median time from CLL diagnosis to development of HV was 5.9 (range=0.8-11.9) years and the median survival was 39.5 months, compared to 9 months for the cases with RS-DLBCL. CONCLUSION: Hodgkin variant appears to differ from DLBCL-RS and is clinically less aggressive. However, compared to de novo Hodgkin's lymphoma, HV-RS has a worse prognosis.
Authors: Sameer A Parikh; Thomas M Habermann; Kari G Chaffee; Timothy G Call; Wei Ding; Jose F Leis; William R Macon; Susan M Schwager; Kay M Ristow; Luis F Porrata; Neil E Kay; Susan L Slager; Tait D Shanafelt Journal: Am J Hematol Date: 2015-01-30 Impact factor: 10.047
Authors: Andrew D Zelenetz; Leo I Gordon; William G Wierda; Jeremy S Abramson; Ranjana H Advani; C Babis Andreadis; Nancy Bartlett; John C Byrd; Myron S Czuczman; Luis E Fayad; Richard I Fisher; Martha J Glenn; Thomas M Habermann; Nancy Lee Harris; Richard T Hoppe; Steven M Horwitz; Christopher R Kelsey; Youn H Kim; Susan Krivacic; Ann S LaCasce; Auayporn Nademanee; Pierluigi Porcu; Oliver Press; Rachel Rabinovitch; Nishitha Reddy; Erin Reid; Ayman A Saad; Lubomir Sokol; Lode J Swinnen; Christina Tsien; Julie M Vose; Lynn Wilson; Joachim Yahalom; Nadeem Zafar; Mary Dwyer; Hema Sundar Journal: J Natl Compr Canc Netw Date: 2015-03 Impact factor: 11.908
Authors: Rebecca L King; Alia Gupta; Paul J Kurtin; Wei Ding; Timothy G Call; Kari G Rabe; Saad S Kenderian; Jose F Leis; Yucai Wang; Susan M Schwager; Susan L Slager; Neil E Kay; Amber Koehler; Stephen M Ansell; David J Inwards; Thomas M Habermann; Min Shi; Curtis A Hanson; Matthew T Howard; Sameer A Parikh Journal: Blood Cancer J Date: 2022-01-28 Impact factor: 11.037
Authors: Carolina Afonso; Marília Gomes; Marta Isabel Pereira; Carlos Faria; Raquel Pina; Tiago Saraiva; Catarina Geraldes; José Pedro Carda Journal: Clin Case Rep Date: 2022-10-03